Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Sulfur Hexafluoride
Therapeutic Area : Cardiology/Vascular Diseases
Study Phase : Phase III
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lumason® Infusion vs. Bolus Administrations
Details : Lumason is a drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Heart Diseases.
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Inapplicable
May 06, 2024
Lead Product(s) : Sulfur Hexafluoride
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Phase III
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Sulfur Hexafluoride
Therapeutic Area : Oncology
Study Phase : Phase I/ Phase II
Sponsor : NaviFUS
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Lumason is a drug candidate, which is currently being evaluated in phase I/ phase II clinical studies for the treatment of Glioblastoma.
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Inapplicable
March 26, 2024
Lead Product(s) : Sulfur Hexafluoride
Therapeutic Area : Oncology
Highest Development Status : Phase I/ Phase II
Sponsor : NaviFUS
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Sulfur Hexafluoride
Therapeutic Area : Cardiology/Vascular Diseases
Study Phase : Phase I
Sponsor : Burl Concepts
Deal Size : Inapplicable
Deal Type : Inapplicable
Study: SONAS Ultrasound for Detecting Stroke SONAS Ultrasound for Detecting Stroke
Details : Lumason is a drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Stroke.
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Inapplicable
September 28, 2017
Lead Product(s) : Sulfur Hexafluoride
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Phase I
Sponsor : Burl Concepts
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Sulfur Hexafluoride
Therapeutic Area : Orthopedics/Orthopedic Surgery
Study Phase : Phase I
Sponsor : Bracco | Pediatric Orthopaedic Society of North America
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Lumason is a drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Developmental Dysplasia of the Hip.
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Inapplicable
April 11, 2017
Lead Product(s) : Sulfur Hexafluoride
Therapeutic Area : Orthopedics/Orthopedic Surgery
Highest Development Status : Phase I
Sponsor : Bracco | Pediatric Orthopaedic Society of North America
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Sulfur Hexafluoride
Therapeutic Area : Cardiology/Vascular Diseases
Study Phase : Phase III
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Lumason is a drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Coronary Artery Disease.
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Inapplicable
September 17, 2015
Lead Product(s) : Sulfur Hexafluoride
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Phase III
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Sulfur Hexafluoride
Therapeutic Area : Cardiology/Vascular Diseases
Study Phase : Phase III
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Lumason is a drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Coronary Artery Disease.
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Inapplicable
August 13, 2015
Lead Product(s) : Sulfur Hexafluoride
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Phase III
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Sulfur Hexafluoride
Therapeutic Area : Ophthalmology
Study Phase : Undisclosed
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Sulfur Hexafluoride is a Other Small Molecule drug candidate, which is currently being evaluated in clinical studies for the treatment of Rhegmatogenous Retinal Detachment, Autosomal Dominant.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
July 09, 2014
Lead Product(s) : Sulfur Hexafluoride
Therapeutic Area : Ophthalmology
Highest Development Status : Undisclosed
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Sulfur Hexafluoride
Therapeutic Area : Oncology
Study Phase : Undisclosed
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Breast Lesions Characterization on Contrast Enhanced Ultrasound With Histopathological Correlation
Details : Sonovue is a Other Small Molecule drug candidate, which is currently being evaluated in clinical studies for the treatment of Breast Neoplasms.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
June 27, 2014
Lead Product(s) : Sulfur Hexafluoride
Therapeutic Area : Oncology
Highest Development Status : Undisclosed
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Sulfur Hexafluoride
Therapeutic Area : Pulmonary/Respiratory Diseases
Study Phase : Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Safety of SonoVue on Pulmonary Hemodynamics
Details : Sonovue is a Other Small Molecule drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Hypertension, Pulmonary.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
March 01, 2011
Lead Product(s) : Sulfur Hexafluoride
Therapeutic Area : Pulmonary/Respiratory Diseases
Highest Development Status : Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable